Bone targeting for the treatment of osteoporosis

Journal of Controlled Release

Volumn 161, Issue 2, 2012, Pages 198-213

  Luhmann, Tessa ^a   Germershaus, Oliver ^a   Groll, Jürgen ^a   Meinel, Lorenz ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

biopharmacy; Bone targeting; osteoporosis; protease sensitive systems; responsive delivery systems

Indexed keywords

ADVANCED TARGETING; AGING POPULATION; BIOPHARMACY; DELIVERY SYSTEMS; DRUG DEVELOPMENT; DRUG-TARGETING; ENVIRONMENTAL STIMULI; OSTEOPOROSIS; SENSITIVE SYSTEMS; THERAPEUTIC POTENTIALS;

BONE;

DISEASES;

BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CATHEPSIN K INHIBITOR; DENOSUMAB; ESTRADIOL; FLUOROURACIL; GADOTERIC ACID; OGX 21; OGX 58; PARATHYROID HORMONE; PARATHYROID HORMONE[1-34]; PROSTAGLANDIN E1; RECOMBINANT BONE MORPHOGENETIC PROTEIN 2; SARACATINIB; SELECTIVE ESTROGEN RECEPTOR MODULATOR; STRONTIUM RANELATE; UNCLASSIFIED DRUG;

BONE CELL; BONE DENSITY; BONE MATRIX; BONE MINERALIZATION; BONE STRENGTH; BONE TURNOVER; CELL FUNCTION; CLINICAL TRIAL (TOPIC); DRUG DELIVERY SYSTEM; DUAL ENERGY X RAY ABSORPTIOMETRY; FRACTURE; HUMAN; LOOSE FECES; NONHUMAN; OSTEOPOROSIS; PAPULAR RASH; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN TARGETING; REVIEW; RISK FACTOR;

ANABOLIC AGENTS; ANIMALS; BONE AND BONES; BONE DENSITY CONSERVATION AGENTS; DRUG DELIVERY SYSTEMS; HUMANS; OSTEOBLASTS; OSTEOPOROSIS;

EID: 84862659745     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2011.10.001     Document Type: Review

References (189)

1. S.R. Cummings, L.J. Melton, Epidemiology and outcomes of osteoporotic fractures, Lancet 359 (2002) 1761-1767.
2. F.H. Netter, T. Böttcher, S. Engelhardt, M. Kortenhaus, Netters Orthopädie, Georg Thieme Verlag, Stuttgart, 2001.
3. U.N.O. Foundation, in: www.nov.org (Ed.), 2011.
4. L.J. Melton III, M. Thamer, N.F. Ray, J.K. Chan, C.H. Chesnut III, T.A. Einhorn, C.C. Johnston, L.G. Raisz, S.L. Silverman, E.S. Siris, Fractures attributable to osteoporosis: report from the National Osteoporosis Foundation, J. Bone Miner. Res. 12 (1997) 16-23.
5. N.F. Ray, J.K. Chan, M. Thamer, L.J. Melton III, Medical expenditures for the treatment of osteoporotic fractures in the United States in 1995: report from the National Osteoporosis Foundation, J. Bone Miner. Res. 12 (1997) 24-35.
6. P. Ammann, R. Rizzoli, Bone strength and its determinants, Osteoporos. Int. 14 (Suppl. 3) (2003) S13-S18.
7. D. Pienkowski, S.R. Pollack, The origin of stress-generated potentials in fluid-saturated bone, J. Orthop. Res. 1 (1983) 30-41.
8. R.M. Davidson, D.W. Tatakis, A.L. Auerbach, Multiple forms of mechanosensitive ion channels in osteoblast-like cells, Pflugers Arch 416 (1990) 646-651.
9. M.L. Cotrina, J.H. Lin, A. Alves-Rodrigues, S. Liu, J. Li, H. Azmi-Ghadimi, J. Kang, C.C. Naus, M. Nedergaard, Connexins regulate calcium signaling by controlling ATP release, Proc. Natl. Acad. Sci. U. S. A. 95 (1998) 15735-15740.
10. A.M. Malone, C.T. Anderson, P. Tummala, R.Y. Kwon, T.R. Johnston, T. Stearns, C.R. Jacobs, Primary cilia mediate mechanosensing in bone cells by a calcium-independent mechanism, Proc. Natl. Acad. Sci. U. S. A. 104 (2007) 13325-13330.
11. R.G. Russell, Z. Xia, J.E. Dunford, U. Oppermann, A. Kwaasi, P.A. Hulley, K.L. Kavanagh, J.T. Triffitt, M.W. Lundy, R.J. Phipps, B.L. Barnett, F.P. Coxon, M.J. Rogers, N.B. Watts, F.H. Ebetino, Bisphosphonates: an update on mechanisms of action and how these relate to clinical efficacy, Ann. N. Y. Acad. Sci. 1117 (2007) 209-257.
12. D. Wang, S.C. Miller, P. Kopeckova, J. Kopecek, Bone-targeting macromolecular therapeutics, Adv Drug Deliv Rev 57 (2005) 1049-1076.
13. A. Badros, D. Weikel, A. Salama, O. Goloubeva, A. Schneider, A. Rapoport, R. Fenton, N. Gahres, E. Sausville, R. Ord, T. Meiller, Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors, J. Clin. Oncol. 24 (2006) 945-952.
14. A.O. Hoff, B.B. Toth, K. Altundag, M.M. Johnson, C.L. Warneke, M. Hu, A. Nooka, G. Sayegh, V. Guarneri, K. Desrouleaux, J. Cui, A. Adamus, R.F. Gagel, G.N. Hortobagyi, Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates, J. Bone Miner. Res. 23 (2008) 826-836.
15. G.G. Kuiper, P.J. Shughrue, I. Merchenthaler, J.A. Gustafsson, The estrogen receptor beta subtype: a novel mediator of estrogen action in neuroendocrine systems, Front. Neuroendocrinol. 19 (1998) 253-286.
16. A.M. Brzozowski, A.C. Pike, Z. Dauter, R.E. Hubbard, T. Bonn, O. Engstrom, L. Ohman, G.L. Greene, J.A. Gustafsson, M. Carlquist, Molecular basis of agonism and antagonism in the oestrogen receptor, Nature 389 (1997) 753-758.
17. L.A. Paige, D.J. Christensen, H. Gron, J.D. Norris, E.B. Gottlin, K.M. Padilla, C.Y. Chang, L.M. Ballas, P.T. Hamilton, D.P. McDonnell, D.M. Fowlkes, Estrogen receptor (ER) modulators each induce distinct conformational changes in ER alpha and ER beta, Proc. Natl. Acad. Sci. U. S. A. 96 (1999) 3999-4004.
18. E. Barrett-Connor, L. Mosca, P. Collins, M.J. Geiger, D. Grady, M. Kornitzer, M.A. McNabb, N.K. Wenger, Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women, N. Engl. J. Med. 355 (2006) 125-137.
19. Y. Shang, M. Brown, Molecular determinants for the tissue specificity of SERMs, Science 295 (2002) 2465-2468.
20. K.W. Peng, H. Wang, Z. Qin, G.T. Wijewickrama, M. Lu, Z. Wang, J.L. Bolton, G.R. Thatcher, Selective estrogen receptor modulator delivery of quinone warheads to DNA triggering apoptosis in breast cancer cells, ACS Chem. Biol. 4 (2009) 1039-1049.
21. J. Reiser, B. Adair, T. Reinheckel, Specialized roles for cysteine cathepsins in health and disease, J. Clin. Invest. 120 (2010) 3421-3431.
22. K.M. Hummel, P.K. Petrow, J.K. Franz, U. Muller-Ladner, W.K. Aicher, R.E. Gay, D. Bromme, S. Gay, Cysteine proteinase cathepsin K mRNA is expressed in synovium of patients with rheumatoid arthritis and is detected at sites of synovial bone destruction, J. Rheumatol. 25 (1998) 1887-1894.
23. D. Bromme, J.L. Klaus, K. Okamoto, D. Rasnick, J.T. Palmer, Peptidyl vinyl sulphones: a new class of potent and selective cysteine protease inhibitors: S2P2 specificity of human cathepsin O2 in comparison with cathepsins S and L, Biochem. J. 315 (Pt 1) (1996) 85-89.
24. J.A. Eisman, H.G. Bone, D.J. Hosking, M.R. McClung, I.R. Reid, R. Rizzoli, H. Resch, N. Verbruggen, C.M. Hustad, C. DaSilva, R. Petrovic, A.C. Santora, B.A. Ince, A. Lombardi, Odanacatib in the treatment of postmenopausal women with low bone mineral density: three-year continued therapy and resolution of effect, J. Bone Miner. Res. 26 (2011) 242-251.
25. C. Deal, Potential new drug targets for osteoporosis, Nat. Clin. Pract. Rheumatol. 5 (2009) 20-27.
26. S.A. Stoch, S. Zajic, J. Stone, D.L. Miller, K. Van Dyck, M.J. Gutierrez, M. De Decker, L. Liu, Q. Liu, B.B. Scott, D. Panebianco, B. Jin, L.T. Duong, K. Gottesdiener, J.A. Wagner, Effect of the cathepsin K inhibitor odanacatib on bone resorption biomarkers in healthy postmenopausal women: two double-blind, randomized, placebo-controlled phase I studies, Clin. Pharmacol. Ther. 86 (2009) 175-182.
27. M. Zaidi, B. Troen, B.S. Moonga, E. Abe, Cathepsin K, osteoclastic resorption, and osteoporosis therapy, J. Bone Miner. Res. 16 (2001) 1747-1749.
28. D.J. Rieman, H.A. McClung, R.A. Dodds, S.M. Hwang, M.W. Holmes, I.E. James, F.H. Drake, M. Gowen, Biosynthesis and processing of cathepsin K in cultured human osteoclasts, Bone 28 (2001) 282-289.
29. S.L. Limited, Summary of Product Characteristics Protelos 2 g granules for oral suspension, in, The electronic Medicines Compendium (eMC) 2011.
30. G.V. Foster, A. Baghdiantz, M.A. Kumar, E. Slack, H.A. Soliman, I. Macintyre, Thyroid origin of calcitonin, Nature 202 (1964) 1303-1305.
31. J. Friedman, L.G. Raisz, Thyrocalcitonin: inhibitor of bone resorption in tissue culture, Science 150 (1965) 1465-1467.
32. M. Zaidi, K. Fuller, P.J. Bevis, R.E. GainesDas, T.J. Chambers, I. MacIntyre, Calcitonin gene-related peptide inhibits osteoclastic bone resorption: a comparative study, Calcif. Tissue Int. 40 (1987) 149-154.
33. D.L. Hurley, R.D. Tiegs, H.W. Wahner, H. Heath III, Axial and appendicular bone mineral density in patients with long-term deficiency or excess of calcitonin, N. Engl. J. Med. 317 (1987) 537-541.
34. M.A. Karsdal, B.C. Sondergaard, M. Arnold, C. Christiansen, Calcitonin affects both bone and cartilage: a dual action treatment for osteoarthritis? Ann. N. Y. Acad. Sci. 1117 (2007) 181-195.
35. K.H. Bhandari, M. Newa, H. Uludag, M.R. Doschak, Synthesis, characterization and in vitro evaluation of a bone targeting delivery system for salmon calcitonin, Int. J. Pharm. 394 (2010) 26-34.
36. T.D. Rachner, S. Khosla, L.C. Hofbauer, Osteoporosis: now and the future, Lancet 377 (2011) 1276-1287.
37. J.P. Brown, R.L. Prince, C. Deal, R.R. Recker, D.P. Kiel, L.H. de Gregorio, P. Hadji, L.C. Hofbauer, J.M. Alvaro-Gracia, H. Wang, M. Austin, R.B. Wagman, R. Newmark, C. Libanati, J. San Martin, H.G. Bone, Comparison of the effect of denosumab and alendronate on bone mineral density and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial, J. Bone Miner. Res. (2009) 1-34.
38. J.P. Brown, R.L. Prince, C. Deal, R.R. Recker, D.P. Kiel, L.H. de Gregorio, P. Hadji, L.C. Hofbauer, J.M. Alvaro-Gracia, H. Wang, M. Austin, R.B. Wagman, R. Newmark, C. Libanati, J. San Martin, H.G. Bone, Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial, J. Bone Miner. Res. 24 (2009) 153-161.
39. S.R. Cummings, J. San Martin, M.R. McClung, E.S. Siris, R. Eastell, I.R. Reid, P. Delmas, H.B. Zoog, M. Austin, A. Wang, S. Kutilek, S. Adami, J. Zanchetta, C. Libanati, S. Siddhanti, C. Christiansen, Denosumab for prevention of fractures in postmenopausal women with osteoporosis, N. Engl. J. Med. 361 (2009) 756-765.
40. Amgen, Summary of Product Characteristics in, , 2010.
41. P. Soriano, C. Montgomery, R. Geske, A. Bradley, Targeted disruption of the c-src proto-oncogene leads to osteopetrosis in mice, Cell 64 (1991) 693-702.
42. L.M. Calvi, N.A. Sims, J.L. Hunzelman, M.C. Knight, A. Giovannetti, J.M. Saxton, H.M. Kronenberg, R. Baron, E. Schipani, Activated parathyroid hormone/parathyroid hormone-related protein receptor in osteoblastic cells differentially affects cortical and trabecular bone, J. Clin. Invest. 107 (2001) 277-286.
43. C.A. O'Brien, L.I. Plotkin, C. Galli, J.J. Goellner, A.R. Gortazar, M.R. Allen, A.G. Robling, M. Bouxsein, E. Schipani, C.H. Turner, R.L. Jilka, R.S. Weinstein, S.C. Manolagas, T. Bellido, Control of bone mass and remodeling by PTH receptor signaling in osteocytes, PLoS One 3 (2008) e2942.
44. I. Kramer, G.G. Loots, A. Studer, H. Keller, M. Kneissel, Parathyroid hormone (PTH)-induced bone gain is blunted in SOST overexpressing and deficient mice, J. Bone Miner. Res. 25 (2010) 178-189.
45. T. Ponnapakkam, R. Katikaneni, E. Miller, A. Ponnapakkam, S. Hirofumi, S. Miyata, L.J. Suva, J. Sakon, O. Matsushita, R.C. Gensure, Monthly administration of a novel PTH-collagen binding domain fusion protein is anabolic in mice, Calcif. Tissue Int. 88 (2011) 511-520.
46. G.G. Loots, M. Kneissel, H. Keller, M. Baptist, J. Chang, N.M. Collette, D. Ovcharenko, I. Plajzer-Frick, E.M. Rubin, Genomic deletion of a long-range bone enhancer misregulates sclerostin in Van Buchem disease, Genome Res. 15 (2005) 928-935.
47. D. Padhi, G. Jang, B. Stouch, L. Fang, E. Posvar, Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody, J. Bone Miner. Res. 26 (2011) 19-26.
48. D.G. Winkler, M.K. Sutherland, J.C. Geoghegan, C. Yu, T. Hayes, J.E. Skonier, D. Shpektor, M. Jonas, B.R. Kovacevich, K. Staehling-Hampton, M. Appleby, M.E. Brunkow, J.A. Latham, Osteocyte control of bone formation via sclerostin, a novel BMP antagonist, EMBO J. 22 (2003) 6267-6276.
49. L. Pederson, M. Ruan, J.J. Westendorf, S. Khosla, M.J. Oursler, Regulation of bone formation by osteoclasts involves Wnt/BMP signaling and the chemokine sphingosine-1-phosphate, Proc. Natl. Acad. Sci. U. S. A. 105 (2008) 20764-20769.
50. R. Baron, G. Rawadi, Targeting the Wnt/beta-catenin pathway to regulate bone formation in the adult skeleton, Endocrinology 148 (2007) 2635-2643.
51. B. Mao, W. Wu, G. Davidson, J. Marhold, M. Li, B.M. Mechler, H. Delius, D. Hoppe, P. Stannek, C. Walter, A. Glinka, C. Niehrs, Kremen proteins are Dickkopf receptors that regulate Wnt/beta-catenin signalling, Nature 417 (2002) 664-667.
52. H. Suzuki, D.N. Watkins, K.W. Jair, K.E. Schuebel, S.D. Markowitz, W.D. Chen, T.P. Pretlow, B. Yang, Y. Akiyama, M. Van Engeland, M. Toyota, T. Tokino, Y. Hinoda, K. Imai, J.G. Herman, S.B. Baylin, Epigenetic inactivation of SFRP genes allows constitutive WNT signaling in colorectal cancer, Nat. Genet. 36 (2004) 417-422.
53. M. van de Wetering, E. Sancho, C. Verweij, W. de Lau, I. Oving, A. Hurlstone, K. van der Horn, E. Batlle, D. Coudreuse, A.P. Haramis, M. Tjon-Pon-Fong, P. Moerer, M. van den Born, G. Soete, S. Pals, M. Eilers, R. Medema, H. Clevers, The betacatenin/TCF-4 complex imposes a crypt progenitor phenotype on colorectal cancer cells, Cell 111 (2002) 241-250.
54. M. Kansara, M. Tsang, L. Kodjabachian, N.A. Sims, M.K. Trivett, M. Ehrich, A. Dobrovic, J. Slavin, P.F. Choong, P.J. Simmons, I.B. Dawid, D.M. Thomas, Wnt inhibitory factor 1 is epigenetically silenced in human osteosarcoma, and targeted disruption accelerates osteosarcomagenesis in mice, J. Clin. Invest. 119 (2009) 837-851.
55. G.H. Enders, Wnt therapy for bone loss: golden goose or Trojan horse? J. Clin. Invest. 119 (2009) 758-760.
56. L.H. Hoeppner, F.J. Secreto, J.J. Westendorf, Wnt signaling as a therapeutic target for bone diseases, Expert Opin Ther Targets 13 (2009) 485-496.
57. D. Diarra, M. Stolina, K. Polzer, J. Zwerina, M.S. Ominsky, D. Dwyer, A. Korb, J. Smolen, M. Hoffmann, C. Scheinecker, D. van der Heide, R. Landewe, D. Lacey, W.G. Richards, G. Schett, Dickkopf-1 is a master regulator of joint remodeling, Nat Med 13 (2007) 156-163.
58. O. Johnell, J.A. Kanis, An estimate of the worldwide prevalence, mortality and disability associated with hip fracture, Osteoporos. Int. 15 (2004) 897-902.
59. C.M. Bagi, D. Wilkie, K. Georgelos, D. Williams, D. Bertolini, Morphological and structural characteristics of the proximal femur in human and rat, Bone 21 (1997) 261-267.
60. A.M. Pankovich, Primary internal fixation of femoral neck fractures, Arch. Surg. 110 (1975) 20-26.
61. D. Phemister, The pathology of ununited fractures of the neck of the femur with special reference to the head, J Bone Joint Surg Am 21 (1939) 681-693.
62. J.E. Shea, E.G. Vajda, R.D. Bloebaum, Evidence of a hypermineralised calcified fibrocartilage on the human femoral neck and lesser trochanter, J. Anat. 198 (2001) 153-162.
63. E.G. Vajda, R.D. Bloebaum, Age-related hypermineralization in the female proximal human femur, Anat. Rec. 255 (1999) 202-211.
64. G. Zagba-Mongalima, M. Goret-Nicaise, A. Dhem, Age changes in human bone: a microradiographic and histological study of subperiosteal and periosteal calcifications, Gerontology 34 (1988) 264-276.
65. V. Bousson, F. Peyrin, C. Bergot, M. Hausard, A. Sautet, J.D. Laredo, Cortical bone in the human femoral neck: three-dimensional appearance and porosity using synchrotron radiation, J. Bone Miner. Res. 19 (2004) 794-801.
66. T.M. Boyce, R.D. Bloebaum, Cortical aging differences and fracture implications for the human femoral neck, Bone 14 (1993) 769-778.
67. M.R. Allen, D.B. Burr, Human femoral neck has less cellular periosteum, and more mineralized periosteum, than femoral diaphyseal bone, Bone 36 (2005) 311-316.
68. J. Beattie, G.J. Allan, J.D. Lochrie, D.J. Flint, Insulin-like growth factor-binding protein-5 (IGFBP-5): a critical member of the IGF axis, Biochem. J. 395 (2006) 1-19.
69. R.J. Midura, X. Su, J.A. Morcuende, M. Tammi, R. Tammi, Parathyroid hormone rapidly stimulates hyaluronan synthesis by periosteal osteoblasts in the tibial diaphysis of the growing rat, J. Biol. Chem. 278 (2003) 51462-51468.
70. J.C. Crockett, M.J. Rogers, F.P. Coxon, L.J. Hocking, M.H. Helfrich, Bone remodelling at a glance, J Cell Sci 124 (2011) 991-998.
71. S. Weiner, W. Traub, Bone structure: from angstroms to microns, FASEB J. 6 (1992) 879-885.
72. H.A. Goldberg, K.J. Warner, M.J. Stillman, G.K. Hunter, Determination of the hydroxyapatite-nucleating region of bone sialoprotein, Connect Tissue Res 35 (1996) 385-392.
73. G.K. Hunter, C.L. Kyle, H.A. Goldberg, Modulation of crystal formation by bone phosphoproteins: structural specificity of the osteopontin-mediated inhibition of hydroxyapatite formation, Biochem. J. 300 (Pt 3) (1994) 723-728.
74. W.T. Butler, The nature and significance of osteopontin, Connect Tissue Res 23 (1989) 123-136.
75. F. Lamoureux, M. Baud'huin, L. Duplomb, D. Heymann, F. Redini, Proteoglycans: key partners in bone cell biology, BioEssays 29 (2007) 758-771.
76. A. Hildebrand, M. Romaris, L.M. Rasmussen, D. Heinegard, D.R. Twardzik, W.A. Border, E. Ruoslahti, Interaction of the small interstitial proteoglycans biglycan, decorin and fibromodulin with transforming growth factor beta, Biochem. J. 302 (Pt 2) (1994) 527-534.
77. Y. Mochida, D. Parisuthiman, M. Yamauchi, Biglycan is a positive modulator of BMP-2 induced osteoblast differentiation, Adv Exp Med Biol 585 (2006) 101-113.
78. X.D. Chen, L.W. Fisher, P.G. Robey, M.F. Young, The small leucine-rich proteoglycan biglycan modulates BMP-4-induced osteoblast differentiation, FASEB J. 18 (2004) 948-958.
79. E. Tufvesson, G. Westergren-Thorsson, Tumour necrosis factor-alpha interacts with biglycan and decorin, FEBS Lett. 530 (2002) 124-128.
80. K.J. Noonan, J.W. Stevens, R. Tammi, M. Tammi, J.A. Hernandez, R.J. Midura, Spatial distribution of CD44 and hyaluronan in the proximal tibia of the growing rat, Journal of orthopaedic research: official publication of the Orthopaedic Research Society 14 (1996) 573-581.
81. A.I. Alford, K.D. Hankenson, Matricellular proteins: extracellular modulators of bone development, remodeling, and regeneration, Bone 38 (2006) 749-757.
82. L.C. Armstrong, P. Bornstein, Thrombospondins 1 and 2 function as inhibitors of angiogenesis, Matrix Biol 22 (2003) 63-71.
83. J.F. Riou, M. Umbhauer, D.L. Shi, J.C. Boucaut, Tenascin: a potential modulator of cell-extracellular matrix interactions during vertebrate embryogenesis, Biol Cell 75 (1992) 1-9.
84. L. Wang, C. Ciani, S.B. Doty, S.P. Fritton, Delineating bone's interstitial fluid pathway in vivo, Bone 34 (2004) 499-509.
85. S. Weinbaum, S.C. Cowin, Y. Zeng, A model for the excitation of osteocytes by mechanical loading-induced bone fluid shear stresses, J. Biomech. 27 (1994) 339-360.
86. L. Ouyang, D. He, J. Zhang, G. He, B. Jiang, Q. Wang, Z. Chen, J. Pan, Y. Li, L. Guo, Selective bone targeting 5-fluorouracil prodrugs: synthesis and preliminary biological evaluation, Bioorg. Med. Chem. 19 (2011) 3750-3756.
87. J.L. Millan, S. Narisawa, I. Lemire, T.P. Loisel, G. Boileau, P. Leonard, S. Gramatikova, R. Terkeltaub, N.P. Camacho, M.D. McKee, P. Crine, M.P. Whyte, Enzyme replacement therapy formurine hypophosphatasia, Journal of bone andmineral research: the official journal of the American Society for Bone and Mineral Research 23 (2008) 777-787.
88. H. Pan, P. Kopeckova, J. Liu, D. Wang, S.C. Miller, J. Kopecek, Stability in plasmas of various species of HPMA copolymer-PGE1 conjugates, Pharm. Res. 24 (2007) 2270-2280.
89. B. Chen, H. Lin, J. Wang, Y. Zhao, B. Wang, W. Zhao, W. Sun, J. Dai, Homogeneous osteogenesis and bone regeneration by demineralized bone matrix loading with collagen-targeting bone morphogenetic protein-2, Biomaterials 28 (2007) 1027-1035.
90. T. Nishioka, S. Tomatsu, M.A. Gutierrez, K. Miyamoto, G.G. Trandafirescu, P.L. Lopez, J.H. Grubb, R. Kanai, H. Kobayashi, S. Yamaguchi, G.S. Gottesman, R. Cahill, A. Noguchi, W.S. Sly, Enhancement of drug delivery to bone: characterization of human tissue-nonspecific alkaline phosphatase tagged with an acidic oligopeptide, Mol. Genet. Metab. 88 (2006) 244-255.
91. D. Wang, M. Sima, R.L. Mosley, J.P. Davda, N. Tietze, S.C. Miller, P.R. Gwilt, P. Kopeckova, J. Kopecek, Pharmacokinetic and biodistribution studies of a bonetargeting drug delivery system based on N-(2-hydroxypropyl)methacrylamide copolymers, Mol. Pharm. 3 (2006) 717-725.
92. S.C. Miller, D. Wang, P. Kopeckova, J. Kopecek, Biopolymer-based delivery systems for advanced imaging and skeletal tissue-specific therapeutics, J. Bone Miner. Metab. 23 (Suppl.) (2005) 103-108.
93. K. Yokogawa, K. Miya, T. Sekido, Y. Higashi, M. Nomura, R. Fujisawa, K. Morito, Y. Masamune, Y. Waki, S. Kasugai, K. Miyamoto, Selective delivery of estradiol to bone by aspartic acid oligopeptide and its effects on ovariectomized mice, Endocrinology 142 (2001) 1228-1233.
94. E. Segal, H. Pan, P. Ofek, T. Udagawa, P. Kopeckova, J. Kopecek, R. Satchi-Fainaro, Targeting angiogenesis-dependent calcified neoplasms using combined polymer therapeutics, PLoS One 4 (2009) e5233.
95. E. Segal, H. Pan, L. Benayoun, P. Kopeckova, Y. Shaked, J. Kopecek, R. Satchi-Fainaro, Enhanced anti-tumor activity and safety profile of targeted nanoscaled HPMA copolymer-alendronate-TNP-470 conjugate in the treatment of bone malignances, Biomaterials 32 (2011) 4450-4463.
96. M.R. Doschak, C.M. Kucharski, J.E. Wright, R.F. Zernicke, H. Uludag, Improved bone delivery of osteoprotegerin by bisphosphonate conjugation in a rat model of osteoarthritis, Mol. Pharm. 6 (2009) 634-640.
97. H. Pan, M. Sima, P. Kopeckova, K. Wu, S. Gao, J. Liu, D. Wang, S.C. Miller, J. Kopecek, Biodistribution and pharmacokinetic studies of bone-targeting N-(2-hydroxypropyl) methacrylamide copolymer-alendronate conjugates, Mol. Pharm. 5 (2008) 548-558.
98. J.E. Wright, S.A. Gittens, G. Bansal, P.I. Kitov, D. Sindrey, C. Kucharski, H. Uludag, A comparison of mineral affinity of bisphosphonate-protein conjugates constructed with disulfide and thioether linkages, Biomaterials 27 (2006) 769-784.
99. H. Hirabayashi, J. Fujisaki, Bone-specific drug delivery systems: approaches via chemical modification of bone-seeking agents, Clin. Pharmacokinet. 42 (2003) 1319-1330.
100. L.Y. Park-Wyllie, M.M. Mamdani, D.N. Juurlink, G.A. Hawker, N. Gunraj, P.C. Austin, D.B. Whelan, P.J. Weiler, A. Laupacis, Bisphosphonate use and the risk of subtrochanteric or femoral shaft fractures in older women, Jama 305 (2011) 783-789.
101. K. Watanabe, Collagenolytic proteases from bacteria, Appl. Microbiol. Biotechnol. 63 (2004) 520-526.
102. S. Kasugai, R. Fujisawa, Y. Waki, K. Miyamoto, K. Ohya, Selective drug delivery system to bone: small peptide (Asp)6 conjugation, Journal of bone and mineral research: the official journal of the American Society for Bone and Mineral Research 15 (2000) 936-943.
103. M.B. Murphy, J.D. Hartgerink, A. Goepferich, A.G. Mikos, Synthesis and in vitro hydroxyapatite binding of peptides conjugated to calcium-binding moieties, Biomacromolecules 8 (2007) 2237-2243.
104. D. Wang, S.C. Miller, L.S. Shlyakhtenko, A.M. Portillo, X.M. Liu, K. Papangkorn, P. Kopeckova, Y. Lyubchenko, W.I. Higuchi, J. Kopecek, Osteotropic Peptide that differentiates functional domains of the skeleton, Bioconjug Chem 18 (2007) 1375-1378.
105. Z. Liu, Y. Jiao, Y. Wang, C. Zhou, Z. Zhang, Polysaccharides-based nanoparticles as drug delivery systems, Adv Drug Deliv Rev 60 (2008) 1650-1662.
106. J.M.J. Frechet, E.R. Gillies, Development of acid-sensitive copolymer micelles for drug delivery, Pure Appl Chem 76 (2004) 1295-1307.
107. B. Romberg, W.E. Hennink, G. Storm, Sheddable coatings for long-circulating nanoparticles, Pharm. Res. 25 (2008) 55-71.
108. W. Gao, J.M. Chan, O.C. Farokhzad, pH-Responsive nanoparticles for drug delivery, Mol. Pharm. 7 (2010) 1913-1920.
109. J.W. Yoo, N. Doshi, S. Mitragotri, Adaptive micro and nanoparticles: temporal control over carrier properties to facilitate drug delivery, Adv Drug Deliv Rev (2011).
110. E. Gullotti, Y. Yeo, Extracellularly activated nanocarriers: a new paradigm of tumor targeted drug delivery, Mol. Pharm. 6 (2009) 1041-1051.
111. A.J. D'Souza, E.M. Topp, Release from polymeric prodrugs: linkages and their degradation, J. Pharm. Sci. 93 (2004) 1962-1979.
112. F. Kratz, I.A. Muller, C. Ryppa, A. Warnecke, Prodrug strategies in anticancer chemotherapy, ChemMedChem 3 (2008) 20-53.
113. M. Hruby, T. Etrych, J. Kucka, M. Forsterova, K. Ulbrich, Hydroxybisphosphonate-containing polymeric drug-delivery systems designed for targeting into bone tissue, J. Appl. Polym. Sci. 101 (2006) 3192-3201.
114. R.G. Schoenmakers, P. van de Wetering, D.L. Elbert, J.A. Hubbell, The effect of the linker on the hydrolysis rate of drug-linked ester bonds, J Control Release 95 (2004) 291-300.
115. M. Oishi, Y. Nagasaki, K. Itaka, N. Nishiyama, K. Kataoka, Lactosylated poly(-ethylene glycol)-siRNA conjugate through acid-labile beta-thiopropionate linkage to construct pH-sensitive polyion complex micelles achieving enhanced gene silencing in hepatoma cells, J. Am. Chem. Soc. 127 (2005) 1624-1625.
116. H. Bruyere, A.D. Westwell, A.T. Jones, Tuning the pH sensitivities of orthoester based compounds for drug delivery applications by simple chemical modification, Bioorg Med Chem Lett 20 (2010) 2200-2203.
117. X. Guo, F.C. Szoka Jr., Steric stabilization of fusogenic liposomes by a low-pH sensitive PEG-diortho ester-lipid conjugate, Bioconjug Chem 12 (2001) 291-300.
118. W.C. Shen, H.J.P. Ryser, Cis-aconityl spacer between daunomycin and macromolecular carriers - a model of ph-sensitive linkage releasing drug from a lysosomotropic conjugate, Biochem Bioph Res Co 102 (1981) 1048-1054.
119. D.B. Rozema, D.L. Lewis, D.H. Wakefield, S.C. Wong, J.J. Klein, P.L. Roesch, S.L. Bertin, T.W. Reppen, Q. Chu, A.V. Blokhin, J.E. Hagstrom, J.A. Wolff, Dynamic Poly-Conjugates for targeted in vivo delivery of siRNA to hepatocytes, P Natl Acad Sci USA 104 (2007) 12982-12987.
120. M. Zloh, E. Dinand, S. Brocchini, Aconityl-derived polymers for biomedical applications. Modeling study of cis-trans isomerisation, Theor Chem Acc 109 (2003) 206-212.
121. E.E. Falco, M. Patel, J.P. Fisher, Recent developments in cyclic acetal biomaterials for tissue engineering applications, Pharm. Res. 25 (2008) 2348-2356.
122. J.M.J. Frechet, R. Jain, S.M. Standley, Synthesis and degradation of pH-sensitive linear poly(amidoamine)s, Macromolecules 40 (2007) 452-457.
123. Q. Zhao, Y. Jia, Y. Xiao, Cathepsin K: a therapeutic target for bone diseases, Biochem Bioph Res Co 380 (2009) 721-723.
124. A.G. Costa, N.E. Cusano, B.C. Silva, S. Cremers, J.P. Bilezikian, Cathepsin K: its skeletal actions and role as a therapeutic target in osteoporosis, Nat. Rev. Rheumatol. 7 (2011) 447-456.
125. P.D. Delmas, Markers of bone turnover for monitoring treatment of osteoporosis with antiresorptive drugs, Osteoporosis international: a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 11 (Suppl 6) (2000) S66-S76.
126. F. Lecaille, Y. Choe, W. Brandt, Z. Li, C.S. Craik, D. Bromme, Selective inhibition of the collagenolytic activity of human cathepsin K by altering its S2 subsite specificity, Biochemistry 41 (2002) 8447-8454.
127. F. Lecaille, D. Bromme, G. Lalmanach, Biochemical properties and regulation of cathepsin K activity, Biochimie 90 (2008) 208-226.
128. H. Pan, P. Kopeckova, D. Wang, J. Yang, S. Miller, J. Kopecek, Water-soluble HPMA copolymer-prostaglandin E1 conjugates containing a cathepsin K sensitive spacer, J Drug Target 14 (2006) 425-435.
129. C.W. Hsu, R.M. Olabisi, E.A. Olmsted-Davis, A.R. Davis, J.L. West, Cathepsin K-sensitive poly(ethylene glycol) hydrogels for degradation in response to bone resorption, J Biomed Mater Res A 98 (2011) 53-62.
130. S.M. Krane, M. Inada, Matrix metalloproteinases and bone, Bone 43 (2008) 7-18.
131. J.M. Delaisse, T.L. Andersen, M.T. Engsig, K. Henriksen, T. Troen, L. Blavier, Matrix metalloproteinases (MMP) and cathepsin K contribute differently to osteoclastic activities, Microsc. Res. Tech. 61 (2003) 504-513.
132. K. Fuller, T.J. Chambers, Localisation of mRNA for collagenase in osteocytic, bone surface and chondrocytic cells but not osteoclasts, J Cell Sci 108 (Pt 6) (1995) 2221-2230.
133. T.L. Andersen, M. del Carmen Ovejero, T. Kirkegaard, T. Lenhard, N.T. Foged, J.M. Delaisse, A scrutiny of matrix metalloproteinases in osteoclasts: evidence for heterogeneity and for the presence of MMPs synthesized by other cells, Bone 35 (2004) 1107-1119.
134. V. Everts, J.M. Delaisse, W. Korper, D.C. Jansen, W. Tigchelaar-Gutter, P. Saftig, W. Beertsen, The bone lining cell: its role in cleaning Howship's lacunae and initiating bone formation, Journal of bone and mineral research: the official journal of the American Society for Bone and Mineral Research 17 (2002) 77-90.
135. C.E. Boumah, N. Selvamurugan, N.C. Partridge, Transcription in the osteoblast: regulatory mechanisms utilized by parathyroid hormone and transforming growth factor-beta, Prog Nucleic Acid Res Mol Biol 80 (2005) 287-321.
136. M.T. Engsig, Q.J. Chen, T.H. Vu, A.C. Pedersen, B. Therkidsen, L.R. Lund, K. Henriksen, T. Lenhard, N.T. Foged, Z. Werb, J.M. Delaisse, Matrix metalloproteinase 9 and vascular endothelial growth factor are essential for osteoclast recruitment into developing long bones, J Cell Biol 151 (2000) 879-889.
137. T. Sato, M. del Carmen Ovejero, P. Hou, A.M. Heegaard, M. Kumegawa, N.T. Foged, J.M. Delaisse, Identification of the membrane-type matrix metalloproteinase MT1-MMP in osteoclasts, J Cell Sci 110 (Pt 5) (1997) 589-596.
138. K. Holmbeck, P. Bianco, J. Caterina, S. Yamada, M. Kromer, S.A. Kuznetsov, M. Mankani, P.G. Robey, A.R. Poole, I. Pidoux, J.M. Ward, H. Birkedal-Hansen, MT1-MMP-deficient mice develop dwarfism, osteopenia, arthritis, and connective tissue disease due to inadequate collagen turnover, Cell 99 (1999) 81-92.
139. L.F. Bonewald, The amazing osteocyte, Journal of bone and mineral research: the official journal of the American Society for Bone and Mineral Research 26 (2011) 229-238.
140. D.G. Vartak, R.A. Gemeinhart, Matrix metalloproteases: underutilized targets for drug delivery, J Drug Target 15 (2007) 1-20.
141. B.E. Turk, L.L. Huang, E.T. Piro, L.C. Cantley, Determination of protease cleavage site motifs using mixture-based oriented peptide libraries, Nat. Biotechnol. 19 (2001) 661-667.
142. H. Nagase, G.B. Fields, Human matrix metalloproteinase specificity studies using collagen sequence-based synthetic peptides, Biopolymers 40 (1996) 399-416.
143. D.B. Logar, R. Komadina, J. Prezelj, B. Ostanek, Z. Trost, J. Marc, Expression of bone resorption genes in osteoarthritis and in osteoporosis, J. Bone Miner. Metab. 25 (2007) 219-225.
144. H. Zhao, G. Cai, J. Du, Z. Xia, L. Wang, T. Zhu, Expression of matrix metalloproteinase-9 mRNA in osteoporotic bone tissues, J Tongji Med Univ 17 (1997) 28-31.
145. J. Li, E.Y. Liao, R.C. Dai, Q.Y. Wei, X.H. Luo, Effects of 17 beta-estradiol on the expression of interstitial collagenases-8 and -13 (MMP-8 and MMP-13) and tissue inhibitor of metalloproteinase-1 (TIMP-1) in ovariectomized rat osteoblastic cells, J. Mol. Histol. 35 (2004) 723-731.
146. G. Wang, H. Uludag, Recent developments in nanoparticle-based drug delivery and targeting systems with emphasis on protein-based nanoparticles, Expert Opin Drug Deliv 5 (2008) 499-515.
147. L. Yang, T.J. Webster, Nanotechnology controlled drug delivery for treating bone diseases, Expert Opin Drug Deliv 6 (2009) 851-864.
148. S.V. Vinogradov, T.K. Bronich, A.V. Kabanov, Nanosized cationic hydrogels for drug delivery: preparation, properties and interactions with cells, Adv Drug Deliv Rev 54 (2002) 135-147.
149. R.A. Petros, J.M. DeSimone, Strategies in the design of nanoparticles for therapeutic applications, Nat Rev Drug Discov 9 (2010) 615-627.
150. F. Alexis, E. Pridgen, L.K. Molnar, O.C. Farokhzad, Factors affecting the clearance and biodistribution of polymeric nanoparticles, Mol. Pharm. 5 (2008) 505-515.
151. Y. Geng, P. Dalhaimer, S. Cai, R. Tsai, M. Tewari, T. Minko, D.E. Discher, Shape effects of filaments versus spherical particles in flow and drug delivery, Nat. Nanotechnol. 2 (2007) 249-255.
152. J.M. DeSimone, T.J. Merkel, S.W. Jones, K.P. Herlihy, F.R. Kersey, A.R. Shields, M. Napier, J.C. Luft, H.L. Wu, W.C. Zamboni, A.Z. Wang, J.E. Bear, Using mechanobiological mimicry of red blood cells to extend circulation times of hydrogel microparticles, P Natl Acad Sci USA 108 (2011) 586-591.
153. P. Decuzzi, B. Godin, T. Tanaka, S.Y. Lee, C. Chiappini, X. Liu, M. Ferrari, Size and shape effects in the biodistribution of intravascularly injected particles, J Control Release 141 (2010) 320-327.
154. P. Kolhar, N. Doshi, S. Mitragotri, Polymer nanoneedle-mediated intracellular drug delivery, Small 7 (2011) 2094-2100.
155. L. Tao, W. Hu, Y. Liu, G. Huang, B.D. Sumer, J. Gao, Shape-specific polymeric nanomedicine: emerging opportunities and challenges, Exp Biol Med (Maywood) 236 (2011) 20-29.
156. E. Simone, B.S. Ding, V. Muzykantov, Targeted delivery of therapeutics to endothelium, Cell Tissue Res 335 (2009) 283-300.
157. J. Fang, H. Nakamura, H. Maeda, The EPR effect: unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect, Adv Drug Deliv Rev 63 (2011) 136-151.
158. H. Sarin, Physiologic upper limits of pore size of different blood capillary types and another perspective on the dual pore theory of microvascular permeability, J. Angiogenes. Res. 2 (2010) 14.
159. S.M. Moghimi, Exploiting bone-marrow microvascular structure for drug-delivery and future therapies, Adv Drug Deliv Rev 17 (1995) 61-73.
160. G. Wang, C. Kucharski, X. Lin, H. Uludag, Bisphosphonate-coated BSA nanoparticles lack bone targeting after systemic administration, J Drug Target 18 (2010) 611-626.
161. V. Hengst, C. Oussoren, T. Kissel, G. Storm, Bone targeting potential of bisphosphonate-targeted liposomes. Preparation, characterization and hydroxyapatite binding in vitro, Int. J. Pharm. 331 (2007) 224-227.
162. E. Cenni, D. Granchi, S. Avnet, C. Fotia, M. Salerno, D. Micieli, M.G.
163. R. Pignatello, E. Cenni, D. Micieli, C. Fotia, M. Salerno, D. Granchi, S. Avnet, M.G. Sarpietro, F. Castelli, N. Baldini, A novel biomaterial for osteotropic drug nanocarriers: synthesis and biocompatibility evaluation of a PLGA-ALE conjugate, Nanomedicine (Lond) 4 (2009) 161-175.
164. T. Anada, Y. Takeda, Y. Honda, K. Sakurai, O. Suzuki, Synthesis of calcium phosphate-binding liposome for drug delivery, Bioorg Med Chem Lett 19 (2009) 4148-4150.
165. S.W. Choi, J.H. Kim, Design of surface-modified poly(D, L-lactide-co-glycolide) nanoparticles for targeted drug delivery to bone, J Control Release 122 (2007) 24-30.
166. C.J.H. Porter, S.M. Moghimi, L. Illum, S.S. Davis, The polyoxyethylene polyoxypropylene block copolymer poloxamer-407 selectively redirects intravenously injected microspheres to sinusoidal endothelial-cells of rabbit bone-marrow, FEBS Lett. 305 (1992) 62-66.
167. C.J.H. Porter, S.M. Moghimi, M.C. Davies, S.S. Davis, L. Illum, Differences in the molecular-weight profile of poloxamer-407 affect its ability to redirect intravenously administered colloids to the bone-marrow, Int. J. Pharm. 83 (1992) 273-276.
168. D.A. Sipkins, X. Wei, J.W. Wu, J.M. Runnels, D. Cote, T.K. Means, A.D. Luster, D.T. Scadden, C.P. Lin, In vivo imaging of specialized bone marrow endothelial microdomains for tumour engraftment, Nature 435 (2005) 969-973.
169. A.P. Mann, T. Tanaka, A. Somasunderam, X. Liu, D.G. Gorenstein, M. Ferrari, E-selectin-targeted porous silicon particle for nanoparticle delivery to the bone marrow, Adv. Mater. (2011).
170. M. Varkey, S.A. Gittens, H. Uludag, Growth factor delivery for bone tissue repair: an update, Expert Opin Drug Deliv 1 (2004) 19-36.
171. J.R. Porter, T.T. Ruckh, K.C. Popat, Bone tissue engineering: a review in bone biomimetics and drug delivery strategies, Biotechnol. Prog. 25 (2009) 1539-1560.
172. M.D. Kofron, X. Li, C.T. Laurencin, Protein- and gene-based tissue engineering in bone repair, Curr. Opin. Biotechnol. 15 (2004) 399-405.
173. S.H. Lee, H. Shin, Matrices and scaffolds for delivery of bioactive molecules in bone and cartilage tissue engineering, Adv Drug Deliv Rev 59 (2007) 339-359.
174. V. Luginbuehl, L. Meinel, H.P. Merkle, B. Gander, Localized delivery of growth factors for bone repair, Eur. J. Pharm. Biopharm. 58 (2004) 197-208.
175. B.V. Slaughter, S.S. Khurshid, O.Z. Fisher, A. Khademhosseini, N.A. Peppas, Hydrogels in regenerative medicine, Adv. Mater. 21 (2009) 3307-3329.
176. M. Hincke, T.A.E. Ahmed, E.V. Dare, Fibrin: a versatile scaffold for tissue engineering applications, Tissue Eng Pt B-Rev 14 (2008) 199-215.
177. L. Yu, J. Ding, Injectable hydrogels as unique biomedical materials, Chem. Soc. Rev. 37 (2008) 1473-1481.
178. A.K. Silva, C. Richard, M. Bessodes, D. Scherman, O.W. Merten, Growth factor delivery approaches in hydrogels, Biomacromolecules 10 (2009) 9-18.
179. I. Arrighi, S. Mark, M. Alvisi, B. von Rechenberg, J.A. Hubbell, J.C. Schense, Bone healing induced by local delivery of an engineered parathyroid hormone prodrug, Biomaterials 30 (2009) 1763-1771.
180. B.S. Kim, S.S. Kim, S.J. Gwak, Orthotopic bone formation by implantation of apatite- coated poly(lactide-co-glycolide)/hydroxyapatite composite particulates and bone morphogenetic protein-2, Journal of Biomedical Materials Research Part A 87A (2008) 245-253.
181. P.A. Janmey, J.P. Winer, J.W. Weisel, Fibrin gels and their clinical and bioengineering applications, J R Soc Interface 6 (2009) 1-10.
182. H.G. Schmoekel, F.E. Weber, J.C. Schense, K.W. Gratz, P. Schawalder, J.A. Hubbell, Bone repair with a form of BMP-2 engineered for incorporation into fibrin cell ingrowth matrices, Biotechnol. Bioeng. 89 (2005) 253-262.
183. L. Meinel, V. Luginbuehl, E. Wenk, A. Koch, B. Gander, H.P. Merkle, Insulin-like growth factor I-releasing alginate-tricalciumphosphate composites for bone regeneration, Pharm. Res. 22 (2005) 940-950.
184. M.P. Lutolf, J.A. Hubbell, Synthetic biomaterials as instructive extracellular microenvironments for morphogenesis in tissue engineering, Nat. Biotechnol. 23 (2005) 47-55.
185. M.P. Lutolf, J.L. Lauer-Fields, H.G. Schmoekel, A.T. Metters, F.E. Weber, G.B. Fields, J.A. Hubbell, Synthetic matrix metalloproteinase-sensitive hydrogels for the conduction of tissue regeneration: engineering cell-invasion characteristics, P Natl Acad Sci USA 100 (2003) 5413-5418.
186. A. Rey-Rico, M. Silva, J. Couceiro, A. Concheiro, C. Alvarez-Lorenzo, Osteogenic efficiency of in situ gelling poloxamine systems with and without bone morphogenetic protein-2, Eur Cell Mater 21 (2011) 317-340.
187. D. Ding, Z. Zhu, R. Li, X. Li, W. Wu, X. Jiang, B. Liu, Nanospheres-incorporated implantable hydrogel as a trans-tissue drug delivery system, ACS Nano 5 (2011) 2520-2534.
188. Y.I. Chung, K.M. Ahn, S.H. Jeon, S.Y. Lee, J.H. Lee, G. Tae, Enhanced bone regeneration with BMP-2 loaded functional nanoparticle-hydrogel complex, J Control Release 121 (2007) 91-99.
189. L. Luca, A.L. Rougemont, B.H. Walpoth, L. Boure, A. Tami, J.M. Anderson, O. Jordan, R. Gurny, Injectable rhBMP-2-loaded chitosan hydrogel composite: osteoinduction at ectopic site and in segmental long bone defect, J Biomed Mater Res A 96 (2011) 66-74.